COMPARISON OF FETUIN A LEVELS BEFORE AND AFTER IMMUNOTHERAPY IN PATIENTS WITH ALLERGIC RHINITIS
dc.contributor.author | Ferda BİLGİR | |
dc.contributor.author | Papatya DEGİRMENCİ | |
dc.contributor.author | Ece ONUR | |
dc.contributor.author | Cengiz KİRMAZ | |
dc.date.accessioned | 2024-07-24T09:14:34Z | |
dc.date.available | 2024-07-24T09:14:34Z | |
dc.date.issued | 2021 | |
dc.description.abstract | Introduction: Role of Fetuin-A, a serum glycoprotein, in various diseases has been reported in different studies. There is no available study yet about Fetuin A in allergic diseases. We aimed to determine the role of Fetuin-A in Allergic Rhinitis (AR). Material and Methods: 30 patients aged over 18 and 30 healthy volunteers due to AR were enrolled in the study. Initial and sixth month serum level and nasal lavage Fetuin-A levels as well as nasal symptom scores were compared. Results: Mean Serum Fetuin-A level of patients with AR was found to be 1010.44 ± 679.84mg/L, while mean nasal Fetuin A level was found 946.52 ± 127.123mg/L. The decrease in serum fetuin A (P=0.046) and nasal Fetuin A (P<0.001) levels and nasal symptoms encountered after treatment were statistically significant. Serum Fetuin A increase was determined as a risk factor for AR development in analysis results (RR:1.009, P<0.001).Conclusion:Determination of the changes that were considered as statistically significant in serum and nasal Fetuin A levels led us to the conclusition that Fetuin-A may be a marker in AR in this study aiming to examine the systemic and local levels of Fetuin A in patients with AR. As a result of the analysis, the increase in serum fetuin A level was found to be a risk factor for AR development (RR: 1.009, P <0.001). | |
dc.identifier.issn | 1305-5151 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/26177 | |
dc.language.iso | eng | |
dc.title | COMPARISON OF FETUIN A LEVELS BEFORE AND AFTER IMMUNOTHERAPY IN PATIENTS WITH ALLERGIC RHINITIS | |
dc.type | Araştırma Makalesi |